Back to Home Pancreatic cancer drug combination shrinks tumours in early trial Health

Pancreatic cancer drug combination shrinks tumours in early trial

Published on November 21, 2026 1 views

A daily cancer pill combined with chemotherapy shrank or eliminated detectable tumours in 60.7% of 61 patients with metastatic pancreatic cancer, researchers reported at a Barcelona oncology meeting on November 20. The phase I/II findings concern daraxonrasib given as initial treatment to people who had not previously received therapy for disease that had spread.

The results came from the RMC-GI-102 study, presented at the EORTC-NCI-AACR Symposium. Daraxonrasib blocks active RAS proteins, which help drive growth in most pancreatic cancers. Participants also received the established chemotherapy drugs gemcitabine and nab-paclitaxel, according to the conference organizers and study sponsor Revolution Medicines.

At the September 28 data cutoff, five patients, or 8.2%, had no cancer detectable on scans. Tumours either shrank or remained stable in 90.2% of participants. Median follow-up was 18.3 months, and median time before disease worsened or patients died was 12.8 months, the organizers reported. An undetectable tumour on a scan does not establish a cure.

The sponsor reported that an estimated 76.6% of participants were alive one year after starting treatment. Common adverse effects included rash, diarrhoea, fatigue and low blood-cell counts; 5% stopped daraxonrasib because of effects attributed to the drug. The early study did not assign patients at random to receive chemotherapy alone, so comparisons with older studies cannot prove the combination extends survival.

The US Food and Drug Administration approved daraxonrasib in August for certain adults with metastatic pancreatic cancer after prior treatment, or those unable to receive multi-drug therapy. That authorization does not cover this new first-line combination. The difference matters because the Barcelona results involve a different stage of treatment and a different drug regimen.

Researchers are now testing daraxonrasib alone and with chemotherapy against chemotherapy alone in the larger phase III RASolute 303 trial. Investigator Wungki Park said the randomized study is needed to determine whether the promising tumour responses produce better outcomes. Until those results arrive, the combination remains an investigational first-line approach.

Sources: EORTC-NCI-AACR Symposium (https://event.eortc.org/ena2026/2026/11/20/metastatic-pancreatic-cancer-responds-well-to-initial-treatment/); Revolution Medicines (https://revmed.gcs-web.com/news-releases/news-release-details/revolution-medicines-presents-updated-phase-12-data-rasonquer); Anadolu Agency (https://www.aa.com.tr/en/health/daily-pill-combined-with-chemotherapy-shrinks-pancreatic-tumors-in-early-trial-researchers/4132020); US FDA (https://www.fda.gov/drugs/cancer-approvals/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma)

Comments